Biohaven Ltd. (BHVN)

37,37 -1,08 (-2,81%) Alla chiusura: 04:00PM EDT

Biohaven Ltd.

215 Church Street
New Haven, CT 06510
United States
203 404 0410
https://www.biohaven.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 239

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Vladimir Coric M.D.	Chairman & CEO	1,96M	N/D	1971
Mr. Matthew Buten	Chief Financial Officer	1,05M	N/D	1961
Dr. Bruce D. Car DACVP, Ph.D.	Chief Scientific Officer	883,03k	N/D	1962
Ms. Kimberly Gentile	Senior Vice President of Clinical Operations	858,65k	N/D	1966
Ms. Deb Young	Director of Regulatory Affairs & Operations	N/D	N/D	N/D
Mr. George C. Clark	VP & Chief Accounting Officer	N/D	N/D	1984
Ms. Jennifer Porcelli	Vice President of Investor Relations	N/D	N/D	N/D
Mr. Warren Volles J.D.	General Counsel & Chief Legal Officer	N/D	N/D	N/D
Mr. Clifford Bechtold M.S.	President, GM of Biohaven Ireland & Chief Compliance Officer	N/D	N/D	N/D
Mr. John Tilton	Chief Commercial Officer of Rare Diseases	N/D	N/D	1968

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Governance aziendale

L'ISS Governance QualityScore di Biohaven Ltd. al 1 maggio 2024 è 5. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 8; diritti degli azionisti: 3; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.